Clinical Research Directory
Browse clinical research sites, groups, and studies.
Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients
Sponsor: Tongji University
Summary
This study used polysomnographic technology and randomly selected 60 patients who met the diagnostic criteria for depression and non-organic insomnia as stipulated in DSM-5 into an intervention group (n=30) and a control group (n=30). The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone, while the control group was given citalopram hydrobromide combined with zolpidem. Both groups underwent PSG at baseline and 1 week after medication, and were assessed with the 17-item Hamilton Depression Rating Scale, Zung Self-Rating Depression Scale, Pittsburgh Sleep Quality Index, Arnsworth Insomnia Severity Scale, Antidepressant Side Effects Checklist, and the Drug Dependence Scale neuropsychological assessment at baseline, 1, 2, and 4 weeks after medication. The study aimed to explore the effects of single use of SMAs class antidepressants versus combination with other antidepressants on non-rapid eye movement sleep stage III in patients with depression and insomnia comorbidity, and to compare the effects of depression and insomnia in the two groups.
Official title: Impact of Trazodone on Non-rapid Eye Movement Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-01-01
Completion Date
2027-12-31
Last Updated
2025-02-19
Healthy Volunteers
No
Conditions
Interventions
5-hydroxytryptamine balanced antidepressants trazodone
The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone
Citalopram hydrobromide combined with zolpidem
the control group was given citalopram hydrobromide combined with zolpidem
Locations (1)
Tongji University
Shanghai, Shanghai Municipality, China